Il nostro contributo

L’impatto scientifico misura l’influenza e la rilevanza delle scoperte e delle pubblicazioni di un istituto di ricerca. Per IFOM, l’impatto scientifico non si limita solo alla quantità di pubblicazioni, ma si estende alla qualità delle riviste su cui vengono pubblicati i nostri studi, alla visibilità dei nostri risultati e alla capacità di trasformare queste scoperte in avanzamenti concreti nella lotta contro il cancro.

Avolio M, Leto SM, Sassi F, Lupo B, Grassi E, Catalano I, Zanella ER, Vurchio V, Cottino F, Tsantoulis PK, Lazzari L, Luraghi P, Ferri M, Galimi F, Berrino E, Bellomo SE, Viviani M, Sogari A, Mauri G, Tosi F, Cruciani F, Sartore-Bianchi A, Siena S, Borghi F, Torri V, Élez E, Tabernero J, Nieva M, Montagut C, Tarazona N, Cervantes A, Tejpar S, Bardelli A, Marchiò C, Marsoni S, Bertotti A, Trusolino L

The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer.

Cancer Discov 2026; 270-295. doi: 10.1158/2159-8290.CD-24-0556

Eli S, Rauso G, Ghezzi P, Szczerkowski JLA, Bruzzi M, Rizzelli F, Iommazzo F, Loffreda A, Castagna F, Donà F, Gaddoni C, Dondi A, Marenda M, Rodighiero S, Tournier P, Lavagnino Z, Parazzoli D, Gauthier NC, Tamburri S, Pasini D, Habib SJ, Mapelli M

Localized Wnt-signaling promotes asymmetric NuMA-dependent oriented divisions and unequal apportioning of mitochondria.

Nat Commun 2025; 10690. doi: 10.1038/s41467-025-65775-z

Ponzo M, Drufuca L, Buracchi C, Sindoni MM, Nucera S, Bugarin C, Bason R, Rossetti G, Bonnal R, Meli C, Rambaldi B, Lussana F, Ferrari S, Moretti A, Dastoli G, Risca G, Pellegrino C, Manz MG, Galimberti S, Rambaldi A, Gaipa G, Biondi A, Pagani M, Magnani CF

Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance.

J Immunother Cancer 2025; . doi: 10.1136/jitc-2025-011768

Alaimo A, Carbone FG, Buzo K, Annesi N, Genovesi S, Lorenzato A, Widmann K, Libergoli M, Marmocchi E, Bertalot G, Brolese A, Papotti MG, Molinaro L, Caffo O, Barbareschi M, Bardelli A, Romanel A, Arena S, Lunardi A

TRPM8 levels determine tumor vulnerability to channel agonists.

Mol Oncol 2025; 2905-2920. doi: 10.1002/1878-0261.70049

Vitiello PP, Valsecchi AA, Duregon E, Di Celle PF, Cassoni P, Papotti M, Bardelli A, Di Maio M

KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges.

Cancers (Basel) 2025; . doi: 10.3390/cancers17172803

Brunet L, Alexandre D, Lee J, Blanquer-Rosselló MDM, Bracquemond D, Guernet A, Chhouri H, Goupil M, Kherrouche Z, Arabo A, Mancini M, Cartier D, Yao S, Godefroy D, Dehedin J, Li JR, Duparc C, Jamme P, Vinchent A, Bérard C, Tulasne D, Arena S, Bardelli A, Cheng C, Cho BC, Wurtz O, Coulouarn C, Maraver A, Aaronson SA, Cortot AB, Anouar Y, Grumolato L

Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells.

Nat Commun 2025; 7853. doi: 10.1038/s41467-025-61788-w

D'Oria C, Cincinelli G, Bason R, Pisati F, Simoncello F, Scotti I, Giudice L, Suardi I, Ferrua P, Fossati C, Randelli PS, Caporali R, Pagani M, Ingegnoli F

Patient-Derived Explants of Osteoarthritic Synovium as Ex Vivo Model for Preclinical Research.

Int J Mol Sci 2025; . doi: 10.3390/ijms26146665

Marasco M, Kumar D, Garcia Borrego S, Seale T, Maddalena G, Mezzadra R, Belanger K, Cole S, Perez B, Luan W, Mukherjee R, Aricescu I, Markov V, Zhu Y, Arena S, Bardelli A, de Stanchina E, Lowe SW, Burkhart RA, Zimmerman JW, Yaeger R, Kopetz SE, Rosen N, Misale S

Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations.

Cancer Discov 2025; 1392-1409. doi: 10.1158/2159-8290.CD-24-0614

Grassi E, Vurchio V, Cresswell GD, Catalano I, Lupo B, Sassi F, Galimi F, Borgato S, Ferri M, Viviani M, Pompei S, Urgese G, Chen B, Zanella ER, Cottino F, Russo M, Mauri G, Pietrantonio F, Zampino MG, Lazzari L, Marsoni S, Bardelli A, Lagomarsino MC, Sottoriva A, Trusolino L, Bertotti A

Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer.

Sci Transl Med 2025; eado1641. doi: 10.1126/scitranslmed.ado1641

Alcon C, Kovatcheva M, Morales-Sánchez P, López-Polo V, Torres T, Puig S, Lu A, Samitier J, Enrich C, Serrano M, Montero J

HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells.

Cell Death Differ 2025; 646-656. doi: 10.1038/s41418-024-01417-z

Stier AB, Bonaiuti P, Juhász J, Gross F, Ciliberto A

lncreased risk of slippage upon disengagement of the mitotic checkpoint.

PLoS Comput Biol 2025; e1012879. doi: 10.1371/journal.pcbi.1012879

Bonilla-Quintana M, Ghisleni A, Gauthier NC, Rangamani P

Dynamic mechanisms for membrane skeleton transitions.

J Cell Sci 2025; . doi: 10.1242/jcs.263473

Protasoni M, López-Polo V, Stephan-Otto Attolini C, Brandariz J, Herranz N, Mateo J, Ruiz S, Fernandez-Capetillo O, Kovatcheva M, Serrano M

Cyclophilin D plays a critical role in the survival of senescent cells.

EMBO J 2024; 5972-6000. doi: 10.1038/s44318-024-00259-2

Pham VC, Rödel CJ, Valentino M, Malinverno M, Paolini A, Münch J, Pasquier C, Onyeogaziri FC, Lazovic B, Girard R, Koskimäki J, Hußmann M, Keith B, Jachimowicz D, Kohl F, Hagelkruys A, Penninger JM, Schulte-Merker S, Awad IA, Hicks R, Magnusson PU, Faurobert E, Pagani M, Abdelilah-Seyfried S

Epigenetic regulation by polycomb repressive complex 1 promotes cerebral cavernous malformations.

EMBO Mol Med 2024; 2827-2855. doi: 10.1038/s44321-024-00152-9

Pessei V, Macagno M, Mariella E, Congiusta N, Battaglieri V, Battuello P, Viviani M, Gionfriddo G, Lamba S, Lorenzato A, Oddo D, Idrees F, Cavaliere A, Bartolini A, Guarrera S, Linnebacher M, Monteonofrio L, Cardone L, Milella M, Bertotti A, Soddu S, Grassi E, Crisafulli G, Bardelli A, Barault L, Di Nicolantonio F

DNA demethylation triggers cell free DNA release in colorectal cancer cells.

Genome Med 2024; 118. doi: 10.1186/s13073-024-01386-5

Russo M, Chen M, Mariella E, Peng H, Rehman SK, Sancho E, Sogari A, Toh TS, Balaban NQ, Batlle E, Bernards R, Garnett MJ, Hangauer M, Leucci E, Marine JC, O'Brien CA, Oren Y, Patton EE, Robert C, Rosenberg SM, Shen S, Bardelli A

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.

Nat Rev Cancer 2024; 694-717. doi: 10.1038/s41568-024-00737-z

Siciliano MC, Bertolazzi G, Morello G, Tornambè S, Del Corvo M, Granai M, Sapienza MR, Leahy CI, Fennell E, Belmonte B, Arcuri F, Vannucchi M, Mancini V, Guazzo R, Boccacci R, Onyango N, Nyagol J, Santi R, Di Stefano G, Ferrara D, Bellan C, Marafioti T, Ott G, Siebert R, Quintanilla-Fend L, Fend F, Murray P, Tripodo C, Pileri S, Lazzi S, Leoncini L

Tumor microenvironment of Burkitt lymphoma: different immune signatures with different clinical behavior.

Blood Adv 2024; 4330-4343. doi: 10.1182/bloodadvances.2023011506

López-Polo V, Maus M, Zacharioudakis E, Lafarga M, Attolini CS, Marques FDM, Kovatcheva M, Gavathiotis E, Serrano M

Release of mitochondrial dsRNA into the cytosol is a key driver of the inflammatory phenotype of senescent cells.

Nat Commun 2024; 7378. doi: 10.1038/s41467-024-51363-0

Valentino M, Malinverno M, Maderna C, Pham VC, Rödel CJ, Zanardi F, Arce M, Drufuca L, Rossetti G, Magnusson PU, Lampugnani MG, Dejana E, Abdelilah-Seyfried S, Pagani M

BMI1 Inhibition Improves Lesion Burden in Cerebral Cavernous Malformations.

Circulation 2024; 738-741. doi: 10.1161/CIRCULATIONAHA.123.067438

Kaivola J, Punovuori K, Chastney MR, Miroshnikova YA, Abdo H, Bertillot F, Krautgasser F, Franco JD, Conway JRW, Follain G, Hagström J, Mäkitie A, Irjala H, Ventelä S, Hamidi H, Scita G, Cerbino R, Wickström SA, Ivaska J

Restoring mechanophenotype reverts malignant properties of ECM-enriched vocal fold cancer.

bioRxiv 2024; . doi: 10.1101/2024.08.22.609159

Hanthi YW, Ramirez-Otero MA, Appleby R, De Antoni A, Joudeh L, Sannino V, Waked S, Ardizzoia A, Barra V, Fachinetti D, Pellegrini L, Costanzo V

RAD51 protects abasic sites to prevent replication fork breakage.

Mol Cell 2024; 3026-3043.e11. doi: 10.1016/j.molcel.2024.07.004

Ogrodnik M, Carlos Acosta J, Adams PD, d'Adda di Fagagna F, Baker DJ, Bishop CL, Chandra T, Collado M, Gil J, Gorgoulis V, Gruber F, Hara E, Jansen-Dürr P, Jurk D, Khosla S, Kirkland JL, Krizhanovsky V, Minamino T, Niedernhofer LJ, Passos JF, Ring NAR, Redl H, Robbins PD, Rodier F, Scharffetter-Kochanek K, Sedivy JM, Sikora E, Witwer K, von Zglinicki T, Yun MH, Grillari J, Demaria M

Guidelines for minimal information on cellular senescence experimentation in vivo.

Cell 2024; 4150-4175. doi: 10.1016/j.cell.2024.05.059

Koppold DA, Breinlinger C, Hanslian E, Kessler C, Cramer H, Khokhar AR, Peterson CM, Tinsley G, Vernieri C, Bloomer RJ, Boschmann M, Bragazzi NL, Brandhorst S, Gabel K, Goldhamer AC, Grajower MM, Harvie M, Heilbronn L, Horne BD, Karras SN, Langhorst J, Lischka E, Madeo F, Mitchell SJ, Papagiannopoulos-Vatopaidinos IE, Papagiannopoulou M, Pijl H, Ravussin E, Ritzmann-Widderich M, Varady K, Adamidou L, Chihaoui M, de Cabo R, Hassanein M, Lessan N, Longo V, Manoogian ENC, Mattson MP, Muhlestein JB, Panda S, Papadopoulou SK, Rodopaios NE, Stange R, Michalsen A

International consensus on fasting terminology.

Cell Metab 2024; 1779-1794.e4. doi: 10.1016/j.cmet.2024.06.013

Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, de Marchena M, Auwardt S, Sayed Ahmed S, Bremer NV, Yang SR, Feng Y, Zhou C, Kong N, Liang R, Xu H, Zhang B, Bardelli A, Toska E, Ventura A, Drilon A, Cocco E

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.

Br J Cancer 2024; 601-610. doi: 10.1038/s41416-024-02760-1

Ghisleni A, Bonilla-Quintana M, Crestani M, Lavagnino Z, Galli C, Rangamani P, Gauthier NC

Mechanically induced topological transition of spectrin regulates its distribution in the mammalian cell cortex.

Nat Commun 2024; 5711. doi: 10.1038/s41467-024-49906-6

Lucini F, Petrini C, Salviato E, Pal K, Rosti V, Gorini F, Santarelli P, Quadri R, Lembo G, Graziano G, Di Patrizio Soldateschi E, Tagliaferri I, Pinatel E, Sebestyén E, Rotta L, Gentile F, Vaira V, Lanzuolo C, Ferrari F

Biochemical properties of chromatin domains define genome compartmentalization.

Nucleic Acids Res 2024; e54. doi: 10.1093/nar/gkae454

Oguchi A, Suzuki A, Komatsu S, Yoshitomi H, Bhagat S, Son R, Bonnal RJP, Kojima S, Koido M, Takeuchi K, Myouzen K, Inoue G, Hirai T, Sano H, Takegami Y, Kanemaru A, Yamaguchi I, Ishikawa Y, Tanaka N, Hirabayashi S, Konishi R, Sekito S, Inoue T, Kere J, Takeda S, Takaori-Kondo A, Endo I, Kawaoka S, Kawaji H, Ishigaki K, Ueno H, Hayashizaki Y, Pagani M, Carninci P, Yanagita M, Parrish N, Terao C, Yamamoto K, Murakawa Y

An atlas of transcribed enhancers across helper T cell diversity for decoding human diseases.

Science 2024; eadd8394. doi: 10.1126/science.add8394

Lorito N, Subbiani A, Smiriglia A, Bacci M, Bonechi F, Tronci L, Romano E, Corrado A, Longo DL, Iozzo M, Ippolito L, Comito G, Giannoni E, Meattini I, Avgustinova A, Chiarugi P, Bachi A, Morandi A

FADS1/2 control lipid metabolism and ferroptosis susceptibility in triple-negative breast cancer.

EMBO Mol Med 2024; 1533-1559. doi: 10.1038/s44321-024-00090-6

Mesa D, Barbieri E, Raimondi A, Freddi S, Miloro G, Jendrisek G, Caldieri G, Quarto M, Schiano Lomoriello I, Malabarba MG, Bresci A, Manetti F, Vernuccio F, Abdo H, Scita G, Lanzetti L, Polli D, Tacchetti C, Pinton P, Bonora M, Di Fiore PP, Sigismund S

A tripartite organelle platform links growth factor receptor signaling to mitochondrial metabolism.

Nat Commun 2024; 5119. doi: 10.1038/s41467-024-49543-z

Mariella E, Grasso G, Miotto M, Buzo K, Reilly NM, Andrei P, Vitiello PP, Crisafulli G, Arena S, Rospo G, Corti G, Lorenzato A, Cancelliere C, Barault L, Gionfriddo G, Linnebacher M, Russo M, Di Nicolantonio F, Bardelli A

Transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer.

Mol Oncol 2024; 1460-1485. doi: 10.1002/1878-0261.13622

Clerici S, Podrini C, Stefanoni D, Distefano G, Cassina L, Steidl ME, Tronci L, Canu T, Chiaravalli M, Spies D, Bell TA, Costa AS, Esposito A, D'Alessandro A, Frezza C, Bachi A, Boletta A

Inhibition of asparagine synthetase effectively retards polycystic kidney disease progression.

EMBO Mol Med 2024; 1379-1403. doi: 10.1038/s44321-024-00071-9

Calabrese L, Ciandrini L, Cosentino Lagomarsino M

How total mRNA influences cell growth.

Proc Natl Acad Sci U S A 2024; e2400679121. doi: 10.1073/pnas.2400679121

Gahlot P, Kravic B, Rota G, van den Boom J, Levantovsky S, Schulze N, Maspero E, Polo S, Behrends C, Meyer H

Lysosomal damage sensing and lysophagy initiation by SPG20-ITCH.

Mol Cell 2024; 1556-1569.e10. doi: 10.1016/j.molcel.2024.02.029

Chaboche Q, Campos-Villalobos G, Giunta G, Dijkstra M, Cosentino Lagomarsino M, Scolari VF

A mean-field theory for predicting single polymer collapse induced by neutral crowders.

Soft Matter 2024; 3271-3282. doi: 10.1039/d3sm01522j

Botticelli A, Caputo R, Scagnoli S, Pisegna S, De Laurentiis M, Curigliano G, Lambertini M, Pantano F, Palazzo A, Paris I, Vernieri C, Tedesco B, Giampaglia M, Palleschi M, Ballatore Z, Alesini D, D'Auria G, Fabbri A, Rossi L, Verrazzo A, Scafetta R, Marinelli D, Sposetti C, Barberi V, Strigari L, Marchetti P, Santini D, Fabi A

Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.

Oncologist 2024; 303-310. doi: 10.1093/oncolo/oyad308

Raucci F, Vernieri C, Di Tano M, Ligorio F, Blaževitš O, Lazzeri S, Shmahala A, Fragale G, Salvadori G, Varano G, Casola S, Buono R, Visco E, de Braud F, Longo VD

Cyclic Fasting-Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia.

Cancer Res 2024; 1133-1148. doi: 10.1158/0008-5472.CAN-23-0295

%PLACEHOLDER%